Primary cutaneous follicle centre lymphoma staging: Difference between revisions

	Primary cutaneous follicle centre lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Primary cutaneous follicle centre lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Primary cutaneous follicle centre lymphoma staging On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Primary cutaneous follicle centre lymphoma staging All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Primary cutaneous follicle centre lymphoma staging
CDC on Primary cutaneous follicle centre lymphoma staging
Primary cutaneous follicle centre lymphoma staging in the news
Blogs on Primary cutaneous follicle centre lymphoma staging
Directions to Hospitals Treating Splenic marginal zone lymphoma
Risk calculators and risk factors for Primary cutaneous follicle centre lymphoma staging

Revision as of 21:02, 1 March 2016

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]

**ISCL/EORTC proposal on TNM classification of cutaneous lymphoma other than MF/SS**
Name	Description	Description
T
	T1	Solitary skin involvement
	T1a	a solitary lesion <5 cm diameter
	T1 b	a solitary >5 cm diameter
	T2	Regional skin involvement: multiple lesions limited to 1 body region or 2 contiguous body regions*
	T2a	all-disease-encompassing in a <15-cm-diameter circular area
	T2 b	all-disease-encompassing in a >15- and <30-cm-diameter circular area
	T2 b	all-disease-encompassing in a >30-cm-diameter circular area
	T3	Generalized skin involvement
	T3a	multiple lesions involving 2 noncontiguous body regions
	T3b	multiple lesions involving ≥3 body regions
N
	N0	No clinical or pathologic lymph node involvement
	N1	Involvement of 1 peripheral lymph node region that drains an area of current or prior skin involvement
	N2	Involvement of 2 or more peripheral lymph node regions or involvement of any lymph node region† that does not drain an area of current or prior skin involvement
	N3	Involvement of central lymph nodes
M
	M0	No evidence of extracutaneous non–lymph node disease
	M1	Extracutaneous non–lymph node disease present

@@ Line 11: / Line 11: @@
 ! style="background: #4479BA;; color:#FFF;" | Description
 |-
-| rowspan="11"| T
+! style="background: #D3D3D3;" rowspan="11"| T
 |-
 | style="text-align: center; padding: 5px 5px; background: #D3D3D3;" | T1
@@ Line 43: / Line 43: @@
 | style="padding: 5px 5px; background: #F5F5F5;" | multiple lesions involving ≥3 body regions
 |-
-| rowspan="5"| N
+! style="background: #D3D3D3;" rowspan="5"| N
 |-
 | style="text-align: center; padding: 5px 5px; background: #D3D3D3;" |  N0
@@ Line 57: / Line 57: @@
 | style="padding: 5px 5px; background: #F5F5F5;" |  Involvement of central lymph nodes
 |-
-| rowspan="3"| M
+! style="background: #D3D3D3;" rowspan="3"| M
 |-
 | style="text-align: center; padding: 5px 5px; background: #D3D3D3;" |  M0